Viveve Medical (NASDAQ:VIVE) Upgraded to Buy at LADENBURG THALM/SH SH

Viveve Medical (NASDAQ:VIVE) was upgraded by equities researchers at LADENBURG THALM/SH SH from a “neutral” rating to a “buy” rating in a research note issued on Tuesday, The Fly reports.

A number of other equities analysts have also issued reports on the company. ValuEngine lowered Viveve Medical from a “buy” rating to a “hold” rating in a report on Saturday, November 23rd. Maxim Group reaffirmed a “hold” rating on shares of Viveve Medical in a research note on Friday, August 9th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $2.24.

NASDAQ VIVE traded up $0.07 during trading hours on Tuesday, hitting $0.93. The company had a trading volume of 858,269 shares, compared to its average volume of 1,116,130. The firm has a market cap of $1.27 million, a P/E ratio of -0.01 and a beta of -0.04. Viveve Medical has a fifty-two week low of $0.80 and a fifty-two week high of $220.00. The business has a fifty day simple moving average of $3.63 and a 200-day simple moving average of $1.67.

Viveve Medical (NASDAQ:VIVE) last posted its earnings results on Thursday, November 7th. The company reported ($13.51) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($16.00) by $2.49. The firm had revenue of $1.05 million during the quarter. Viveve Medical had a negative net margin of 429.71% and a negative return on equity of 2,979.48%. On average, equities research analysts expect that Viveve Medical will post -69 earnings per share for the current fiscal year.

In other news, major shareholder Goldman Sachs Group Inc sold 92,425 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $4.81, for a total value of $444,564.25. Corporate insiders own 5.20% of the company’s stock.

An institutional investor recently bought a new position in Viveve Medical stock. FNY Investment Advisers LLC bought a new stake in shares of Viveve Medical Inc (NASDAQ:VIVE) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 16,136 shares of the company’s stock, valued at approximately $71,000. FNY Investment Advisers LLC owned approximately 1.10% of Viveve Medical as of its most recent SEC filing. Institutional investors and hedge funds own 32.96% of the company’s stock.

Viveve Medical Company Profile

Viveve Medical, Inc designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions. The company offers Viveve System, a radio frequency generator, a reusable hand piece, and single-use treatment tip, as well as other consumable components.

Recommended Story: Short Selling Stocks and Day Traders

The Fly

Analyst Recommendations for Viveve Medical (NASDAQ:VIVE)

Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.